Clinical Trial

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.
Protocol Amendment History 4 changes
notable Trial sites expanded: 17 -> 29 locations 2026-07-31
notable Trial sites expanded: 8 -> 17 locations 2026-06-11
critical Recruitment opened 2026-05-23
notable Trial sites expanded: 0 -> 8 locations 2026-05-23
Trial Details
NCT Number NCT07535034
Lead Sponsor Crystalys Therapeutics
Conditions Gout
Enrollment 90 participants
Start Date 2026-05-08
Primary Completion 2027-07 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-30